SYNOVA HEALTHCARE GR

Gestern erhalten :

Hamburg, 27.12.2007

Einleitung eines Vergleichsverfahrens

SYNOVA HEALTHCARE GROUP INC. REG.SH.D WKN A0HGSU ISIN US 87163H1023

Sehr geehrte Kundin, sehr geehrter Kunde,

die Synova Healthcare Group. Inc. stellte Antrag gemäß Chapter XI des Federal Bankruptcy Act. Dies ist der offizielle Weg, ein Vergleichsverfahren einzuleiten.

Nähere Einzelheiten sind zurzeit nicht bekannt.

Ihr Bestand: xxxxxx

Lagerland: Vereinigte Staaten von Amerika

Sofern uns weitere Informationen zugehen, werden wir Sie unterrichten.

Mit freundlichen Grüßen

Ihre

Deutsche Bank AG

Nochmal zur Erinnerung einen Auszug aus der Empfehlung, die ARIVA hier aufgegriffen hat:

Zitat

Mit Synova Healthcare stelle man den Anlegern eine wirklich außergewöhnliche Investmentchance vor, bei der die Analysten vom "Oberbayerischen Börsenbrief" auf dem aktuellen Schnäppchen-Niveau eine einmalige Kaufgelegenheit mit Vervielfachungspotenzial sehen würden. Denn eines stehe außer Frage: Man befinde sich hier am Anfang eines neuen aufstrebenden Marktes, dem von Experten enormes Potenzial vorhergesagt werde, mit jährlichen Wachstumsraten von bis zu 11 Prozent und einem Marktvolumen von über 6,5 Mrd. USD im Jahr 2008.

Vor dem Hintergrund, dass auch die charttechnische Situation gerade jetzt hochinteressant ist, gibt es für die Experten vom "Oberbayerischen Börsenbrief" bei der Aktie von Synova Healthcare Group nur ein Rating: "strong buy" mit einem anfänglichen Kurspotenzial von über 260%. Ihr Kursziel von 6,00 Euro würden sie dabei lediglich als Zwischenetappe zu langfristig noch höheren Notierungen sehen.

Zitat Ende

Mein Fazit : Alles eine einzige Verar.....

Von: "Rush, Meghan" An: Kopie: Betreff: Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants Datum: 20.09.2007 15:50:29 MEDIA, Pa., Sept. 20 /PRNewswire-FirstCall/ -- Synova Healthcare Group, Inc. , today announced that it completed the sale of approximately $3.3 million in aggregate notional principal amount of its 6.5% senior convertible promissory notes, Series B, due September 19, 2012, and related common stock purchase warrants. This sale was effected as the initial part of an ongoing private placement of notes and warrants in the aggregate notional principal amount of up to $5 million. The notes were sold to certain accredited investors and foreign investors. The notes mature on September 19, 2012 and are convertible into shares of Synova common stock at a conversion rate of one share for every $1.00 of principal and accrued and unpaid interest converted, subject to anti-dilution adjustments for certain corporate transactions. Synova's obligations under the notes are unsecured. As part of this offering, Synova issued a warrant to each purchaser of the notes. The warrants have a term of five years and are exercisable for shares of Synova common stock at a price of $1.00 per share, subject to anti-dilution adjustments for certain corporate transactions. Each warrant entitles the holder to acquire a number of shares of Synova common stock equal to 180% of the number of shares that such holder could acquire upon conversion of such holder's notes. Synova will use the net proceeds received >from this offering to provide continued investment in the Today(R) Sponge, to further expand its growing portfolio of women's health care products, and for general corporate purposes. The offer and sale of these notes required the consent of the holders of Synova's existing 6.5% senior convertible promissory notes due January 12, 2012. As consideration for these consents and certain other waivers of, and amendments to, various agreements related to the January notes, Synova and its subsidiaries agreed to grant to the holders of the January notes a first lien on substantially all of their assets. The securities described in this press release were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. About Synova Healthcare Group, Inc. Synova Healthcare Group, Inc. is committed to delivering innovative products that provide meaningful improvements in women's healthcare. Through its subsidiaries, it is focused on the development, distribution, marketing and sale of women's healthcare products related to contraception, vaginal health, menopause management, fertility planning, obstetrics and personal care. Its goal is to provide healthcare solutions that address every stage of a woman's life. Synova currently markets and sells products under the brand names Today(R), Fem-V(TM), MenoCheck(R) and MenocheckPro(R). The Today(R) Sponge is a hormone-free contraceptive that combines barrier, spermicidal and absorptive methods to prevent conception. Fem-V(TM) is a non-invasive diagnostic test designed to assist women in detecting and diagnosing the presence of elevated vaginal acidity, often indicating a vaginal infection. MenoCheck(R) and MenocheckPro(R) are in-home and in-office non-invasive diagnostic tests used to detect and diagnose the onset of menopause. For more information, please visit Synova's website at http://www.synovahealthcare.com. This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risks and uncertainties include the ability to complete the private placement described in this press release and the other risks and uncertainties discussed in the Company's Form 10-KSB for the year ended December 31, 2006, as filed with the Securities and Exchange Commission on February 26, 2007, and the Company's Form 10-QSB for the six months ended June 30, 2007, as filed with the SEC on August 14, 2007, as well as in the Company's other periodic reports and filings with the SEC. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states. Meghan Rush 1400 N. Providence Road | Suite 6010 | Media, PA 19063 Phone: 610.565.7080 x142 | Fax: 610.565.7081 | Email: mrush@synovahealthcare.com _____________________________________________ Leben und leben lassen - gibt's das bei ARIVA? NÖ !

Von: "Rush, Meghan" An: Kopie: Betreff: Synova Healthcare Group, Inc. Announces Board of Directors Appointments Datum: 09.08.2007 16:00:19 Dear SNVH Stockholders; I am pleased to announce that two very accomplished and well experienced professionals have been appointed to our Board of Directors effective immediately. Please see the press release we issued early this morning which provides a short summary of their biographical information. I hope you will concur with us that these gentlemen will be very welcomed additions to our Board of Directors. Thank you for your ongoing interest in Synova Healthcare Group, Inc. Very kind regards, Stephen King | Chief Executive Officer 1400 N. Providence Road | Suite 6010 | Media, PA19063 Phone: 610.565.7080 x137 | Fax: 610.565.7081 | Email: sking@synovahealthcare.com MEDIA, PA (AUGUST 9, 2007) - Synova Healthcare Group, Inc. (OTCBB: SNVH) today announced the appointment of two non-employee directors to its Board of Directors. Joining the Board of Directors, effective August 8th, 2007, are Alan B. Levin and J. Jeffrey Fox. Mr. Levin and Mr. Fox will serve as directors until the Company’s 2008 Annual Meeting of Stockholders, and until their successors are elected and qualified. Mr. Levin successfully led the Happy Harry’s drug store chain from 1987 until it was acquired by the Walgreen Company in July 2007. During his tenure, Happy Harry’s grew >from 19 to 76 stores, with locations in Delaware, Maryland, Pennsylvania and New Jersey. Mr. Levin is a graduate of TulaneUniversity and the Delaware Law School of Widener University. He previously served as the Executive Assistant and Counsel to United States Senator William V. Roth, Jr. In 2001, Mr. Levin served as Chairman of the National Association of Drug Stores. Mr. Levin is also a past member of the Board of Directors of the United States Chamber of Commerce. Currently, Mr. Levin serves as the Chairman of the Board of the Delaware State Chamber of Commerce and a member of its Executive Committee. He is also a board member of the American Red Cross of the Delmarva Peninsula and a member of the Advisory Board of the University of Delaware’s Lerner College of Business and Economics. Mr. Fox is President of Renard Capital, LLC. He serves as an advisor on acquisitions, divestitures, capital formation and strategies to maximize shareholder value. Mr. Fox has over 25 years of acquisition, divestiture, finance and accounting experience, including fifteen years as chief financial officer of several publicly-traded middle market companies. He is also a founding member of Emerald Asset Management. Mr. Fox served for over three years as Chairman of the Audit Committee on the Board of Directors of Cimnet, Inc. He currently serves on the Library of Congress James Madison Council, the William T. Walters Association of the WaltersArt Museum, as well as the board of directors of the Boys and Girls Clubs of Anne Arundel County. Mr. Fox earned his B.S. degree from King’s College and his MBA from the University of Pittsburgh Katz Graduate School of Business. He is a Certified Public Accountant and a Chartered Financial Analyst. “We welcome the appointment of these esteemed professionals to our Board,” said Stephen King, Chairman and Chief Executive Officer of Synova Healthcare Group, Inc. “We are pleased to have been able to attract such directors with the depth and breadth of experience they bring to our company. We look forward to the contributions of these two new directors as we continue to execute our business strategy”. Dennoch stürzt der Kurs seit dieser Nachricht weiter ab. Was gibt es für eine Erklärung? _____________________________________________ Leben und leben lassen - gibt's das bei ARIVA?

also, wenn jetzt der Kurs nicht bald anspringt.... Ein update per Email: Von: "Rush, Meghan" An: Kopie: Betreff: Article: "The Today Sponge is Back. Doctors, Patients Delighted" posted on NBC Philadelphia Health Section Datum: 02.08.2007 19:48:51 Dear SNVH Shareholders, A terrific article highlighting the Today Sponge was issued this morning, and posted on Philadelphia’s NBC10 website. Please take a moment to review the tremendous news for the product and Synova Healthcare Group (SNVH). LINK: http://www.nbc10.com/health/13804895/detail.html Very kind regards, Stephen King | Chief Executive Officer 1400 N. Providence Road | Suite 6010 | Media, PA19063 Phone: 610.565.7080 x137 | Fax: 610.565.7081 | Email: sking@synovahealthcare.com _____________________________________________ Leben und leben lassen - gibt's das bei ARIVA?